

Supplementary Table 1. Newly acquired unpublished clinical data for cases previously described by our group

Case	Reference	Outcomes			Treatment Details			Clinical Data		Molecular Data
		Overall Survival	PFS	Best Response	Chemo	RT	Surgery	Demographics (Age, Sex)	Disease location/extent	NUT fusion partner
1	4			X	X	X	X		X	
2	4			X	X	X	X		X	
3	4			X	X	X	X		X	
4	4			X	X	X	X		X	
5	4			X	X	X	X		X	
6	23	X	X	X	X	X	X		X	
7	17	X	X	X	X	X	X	X	X	X
8	17	X	X	X	X	X	X	X	X	X
9	17	X	X	X	X	X	X	X	X	X
10	17	X	X	X	X	X	X	X	X	X
11	17	X	X	X	X	X	X	X	X	X
12	17							X	X	X
13	17	X	X	X	X	X	X	X	X	X
14	17	X	X	X	X	X	X	X	X	X
15	17	X	X	X	X	X	X	X	X	X
16	17	X	X	X	X	X	X	X	X	X
17	17							X	X	X
18	24									
19	8, 2									
20	8, 2									
21	18		X	X	X	X	X		X	
22	18									
23	18		X	X	X	X	X			
24	18		X	X	X	X	X			
25	18		X	X	X	X	X			
26	18		X	X	X	X	X			
27	18		X	X	X	X	X			
28	18		X	X	X	X	X			
29	6	X	X							
30	15	X	X							
31	3		X	X	X	X	X		X	
32	13									
33	13									
34	12									
35	22	X	X	X	X	X	X		X	
Total	35	13	21	24	24	24	24	11	20	11

X, new data which is presented in this manuscript, but was not present in the original publication; PFS, progression-free survival; Chemo, chemotherapy; RT, radiation therapy.